338 filings
Page 13 of 17
8-K
mak erma4sl
9 Jan 14
Results of Operations and Financial Condition
12:00am
UPLOAD
hpdw4uell81wt
13 Dec 13
Letter from SEC
12:00am
CORRESP
qtye8 islokj
5 Dec 13
Correspondence with SEC
12:00am
CT ORDER
3t9onf
3 Dec 13
Confidential treatment order
12:00am
UPLOAD
1tsinr
2 Dec 13
Letter from SEC
12:00am
8-K
og9ob8v
31 Oct 13
Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL® Revenue of $20.0 Million and Full Third Quarter 2013 Financial Results
12:00am
8-K
xcyzawy
1 Oct 13
Pacira Pharmaceuticals, Inc. Announces Partnership to Support Uptake of EXPAREL® Among the Orthopedic Marketplace
12:00am
8-K
41i9 934gvprsox6z6
12 Sep 13
Departure of Directors or Certain Officers
12:00am
8-K
4l5f3piuz9 mlzv
6 Aug 13
Pacira Pharmaceuticals, Inc. Reports Second Quarter EXPAREL® Revenue of $15.2 Million and Full Second Quarter 2013 Financial Results
12:00am
8-K
wu3vzc
14 Jun 13
Departure of Directors or Certain Officers
12:00am
8-K
7cwit67pbfafln 4l
29 May 13
Pacira Pharmaceuticals, Inc. Announces Positive Interim Analysis of EXPAREL in Femoral Nerve Block for Total Knee Arthroplasty
12:00am
8-K
yca79et4d0ydtw7
8 May 13
Pacira Pharmaceuticals, Inc. Reports $10.4 Million in First Quarter EXPAREL® Revenue and Full First Quarter 2013 Financial Results
12:00am
ARS
z6e22qix4e
29 Apr 13
Annual report to shareholders
12:00am
DEFA14A
wvlqe0ab94oe3tqxh1m7
25 Apr 13
Additional proxy soliciting materials
12:00am
CT ORDER
thudyudj
17 Apr 13
Confidential treatment order
12:00am
8-K
xxahig3nq z5us
18 Mar 13
Entry into a Material Definitive Agreement
12:00am